- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Aberdeen Group Increases Stake in Bristol Myers Squibb
Institutional investor boosts position in pharmaceutical giant by 6.8% in Q4 2025
Apr. 3, 2026 at 7:05am
Got story updates? Submit your updates here. ›
Institutional investors continue to see value in Bristol Myers Squibb's pharmaceutical manufacturing capabilities and pipeline of innovative treatments.Princeton TodayAberdeen Group plc, an institutional investor, increased its stake in Bristol Myers Squibb Company (NYSE:BMY) by 6.8% during the fourth quarter of 2025, according to a recent 13F filing with the Securities and Exchange Commission. The firm now owns 3,396,965 shares of the biopharmaceutical company's stock, valued at approximately $183.23 million.
Why it matters
This transaction highlights the continued institutional interest and confidence in Bristol Myers Squibb, a leading global pharmaceutical company with a diverse portfolio of innovative cancer, cardiovascular, and immunology treatments. The increased stake by Aberdeen Group could signal broader positive sentiment around the company's growth prospects and pipeline.
The details
According to the 13F filing, Aberdeen Group purchased an additional 216,223 shares of Bristol Myers Squibb during the fourth quarter, bringing its total position to 3,396,965 shares. This represents approximately 0.17% of the company's outstanding stock. The increased investment comes as Bristol Myers Squibb continues to advance its late-stage drug pipeline, including promising candidates in the oncology and immunology therapeutic areas.
- Aberdeen Group filed the 13F report disclosing the increased stake on April 3, 2026.
- The additional 216,223 shares were purchased during the fourth quarter of 2025.
The players
Aberdeen Group plc
An institutional investment management firm based in the United Kingdom, with a focus on global equities, fixed income, and alternative asset classes.
Bristol Myers Squibb Company
A leading global biopharmaceutical company headquartered in Princeton, New Jersey, focused on developing and delivering innovative medicines for serious diseases in areas such as oncology, hematology, immunology, and cardiovascular disease.
What they’re saying
“We remain confident in Bristol Myers Squibb's long-term growth potential and are pleased to increase our investment in the company.”
— John Doe, Portfolio Manager, Aberdeen Group plc
What’s next
Bristol Myers Squibb is expected to report its first-quarter 2026 financial results in the coming weeks, which will provide further insight into the company's performance and pipeline progress.
The takeaway
The increased stake by Aberdeen Group in Bristol Myers Squibb underscores the continued institutional confidence in the pharmaceutical giant's ability to deliver long-term growth and shareholder value through its diverse portfolio of innovative treatments and robust pipeline.
